Document is current
Any future updates will be listed below
-
Authors
Koga, Yusuke
Ikushima, Toru
Hiramoto, Nao
Yoshii, Kengo
Murata, Naoki
Mukai, Atsushi
Yamamoto, Yuji
Mieno, Hiroki
Urata, Yasuo
Ueno, Morio
Sotozono, Chie
-
Funding
Funding for this research was provided by:
Japanese Society of the Promotion of Science (20K18352)
- License Information
-
More Information
Article History
Received: 27 January 2025
Accepted: 26 December 2025
First Online: 31 December 2025
Declarations
:
: Y.U. is the President and CEO of Oncolys BioPharma, Inc., the manufacturer of OBP. M.U. received research support from Oncolys BioPharma, Inc. and from Santen Pharmaceutical Co., Ltd. The other authors have no real or potential conflicts of interest to declare.
: All procedures were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and the study protocols were approved by the Animal Use Committee of Kyoto Prefectural University of Medicine, Kyoto, Japan (approval no. B2021-105). The study is reported in accordance with the ARRIVE guidelines.
